Kailera Therapeutics (KLRA) experienced a significant intraday surge, with its stock price soaring 62.50% during Friday's trading session. This movement marks a volatile start for the biotechnology company as it begins public trading.

The sharp increase follows the company's initial public offering, which was priced at $16 per share to raise approximately $625 million. Prior to trading, indications showed the stock was expected to open well above its IPO price, reflecting robust investor demand. The offering was upsized from the initially marketed number of shares and priced at the high end of its range.

Market enthusiasm stems from Kailera's focus on obesity treatments, particularly its lead product candidate ribupatide, a once-weekly injectable GLP-1 drug in late-stage trials. The weight-loss drug market has seen skyrocketing demand and is projected to generate substantial future sales, with obesity drug developers often attracting premium valuations and takeover interest from larger pharmaceutical companies.